SPONSORED TALKS

	Susan is a Board-Certified Obstetrician-Gynecologist and Certified Menopause Practitioner with 20 years of dedicated experience in managing intricate obstetrical and gynecological conditions. She received her medical degree from the University of New England College of Osteopathic Medicine and completed her OBGYN residency at St Francis Hospital and Medical Center, Now serving as a
Thermo Fisher Scientific Susan Volger, MD "Enhancing Preeclampsia Care with Angiogenic Biomarkers (sFlt-1/PIGF ratio)" 6/5 Thursday 12:40-1:05 PM	Medical Science Liaison, Susan applies her deep clinical understanding to educate on cutting-edge medical advancements, building on her commitment to improve patient care.

	Yves Sabbagh, PhD, is senior vice president and chief scientific officer, joining Inozyme in October 2020. Dr. Sabbagh brings to Inozyme more than 25 years of experience in rare genetic disorders and mineral metabolism with responsibilities leading to the identification and evaluation of novel therapeutic approaches and translating them into clinical candidates.
Inozyme Yves Sabbagh, PhD "Interim Clinical and Safety Data of INZ-701 Treatment in Infants and Young Children with ENPP1 Deficiency" 6/5 Thursday 1:05-1:30 PM	Prior to joining Inozyme, Dr. Sabbagh served as the head of Rare Renal and Musculoskeletal Diseases research at Sanofi. Prior to that executive role, he held scientific roles of increasing responsibility at Sanofi and Genzyme Corporation spanning endocrine, renal and rare bone diseases including driving the strategy for bone indications. Prior to his corporate experience, he

was an instructor at the Harvard Medical School
In the Endocrine unit. Dr. Sabbagh has co-
authored more than 40 peer-reviewed
publications and book chapters and is a member
of
several scientific societies. Dr. Sabbagh received a
BSc in biochemistry from McGill University,
an MSc in microbiology from Université Laval and
a PhD in biology from McGill University.
BSc in biochemistry from McGill University, an MSc in microbiology from Université Laval and a PhD in biology from McGill University.

Billion to One	
6/6 Friday 12:50-1:05 PM	



Boston Children's Hospital Alireza Shamshirsaz, MD "Taming the Raging River: Fetoscopic Laser Photocoagulation in Management of Type II Vasa Previa (FLUMEN Study)" 6/6 Friday 1:05-1:30 PM Alireza A. Shamshirsaz, MD, FACOG, currently serves as the Chief of the Division of Maternal-Fetal Medicine and Surgery, Director of the Fetal Care and Surgery Center (FCSC), Director of Perinatal Surgery Fellowship at Boston Children's Hospital. He has held the position of Professor of Surgery at Harvard Medical School since 2022. Dr. Shamshirsaz is a Fetal Surgeon and is dual board-certified in obstetrics and gynecology as well as maternal fetal medicine. He also holds the positions of Vice Chair of the SMFM Education Committee, Co-editor in Chief of the Clinical Obstetrics and Gynecology Journal, and Chair of the Steering Committee of the North American Fetal Therapy Network (NAFTNet).

Over the course of his professional career in the field of maternal fetal medicine spanning two decades, he has published more than 280 peer-reviewed papers. These primarily focus on complex monochorionic pregnancies, lower urinary tract obstruction, neural tube defects, and placenta accreta spectrum disorders. He has also contributed to and led over 40 systematic reviews and meta-analyses in the field. Additionally, he has spearheaded several international qualitative studies aiming to establish clinical guidelines for controversial topics within the field.

In his current role, Dr. Shamshirsaz's research primarily centers on the following three domains:

1) Innovative Fetal Intervention: Dr. Shamshirsaz and his research team are exploring several innovative surgeries for patients with congenital hydrocephalus and vasa previa (FLUMEN study).

2) Innovative Medical Therapies: He has initiated two projects at his current position: one examining the efficacy of Sirolimus in congenital cervicofacial malformations (MaterPons study) and the other assessing the efficacy of Valacyclovir in treating congenital CMV

infections.
3) Mesenchymal Stem Cells: His team is investigating the potential of MSCs in treating fetal anomalies.



Dr. Souter is a board-certified Ob/Gyn and Clinical Geneticist in the US. She obtained her medical degree and postgraduate research degree from the University of Glasgow. She is a Fellow of the Royal College of Obstetricians and Gynaecologists and worked in the National Health Service in the UK for more than 10 years before moving to the US. Her interests include genetics and womens' healthcare, quality improvement, predictive modeling, and midwifery care in the USA. She is now based in Seattle, WA.

Natera Vivienne Souter, MD, MPH "Innovations in Prenatal Genetic Screening" 6/6 Friday 1:30-1:55 PM "Beyond Aneuploidies, Balancing Innovation with Appropriate Care for Single Gene Disorders" 6/7 Saturday 2:10-2:25 PM

	Vivian has worked in both academic and laboratory settings during her 30+ years as a genetic counselor. She began her career as a genetic counselor at Kaiser Permanente in Northern California and then at a large perinatal and genetics practice in Philadelphia, PA. She joined Genzyme Genetics and later Labcorp as a result of two acquisitions. She served as the President of the National Society of Genetic
Labcorp	counselors in 2000. She is currently the Associate Vice President of clinical education and medical

Vivian Weinblatt, MS, CGC "Prenatal Cell-Free DNA Enhancements and Insights: 14 Years and 4 Million Specimens Later" 6/6 Friday 3:30-4:10 PM affairs, and chairs the publications committee.



Myriad Gabriel Lazarin FirstGene: A Combined Prenatal Screen with Reliability Boosted by Fetal Fraction Amplification and Efficient Simultaneous Maternal-Fetal Assessment 6/7 Saturday 12:10-12:35 PM Gabriel Lazarin is our VP of Medical Affairs at Myriad Women's Health. With 15 years of experience in the diagnostics industry, he leads a department of Medical Science Liaisons and facilitates collaborations between Myriad and key opinion leaders in the reproductive and cancer genetics fields. He is a certified genetic counselor with over a decade of clinical, research, and industry experience. He holds a MS in Genetic Counseling from University of Texas Houston and a BA in Human Biology from Stanford University.

Fulgent	
6/7 Saturday	

	Noa Liscovitch-Brauer, PhD, is Vice President of Research and Development at Identifai Genetics, where she oversees the development of advanced non-invasive prenatal tests (NIPT) leveraging genome sequencing of cell-free DNA (cfDNA). With extensive expertise in computational biology, Dr. Liscovitch-Brauer specializes in designing innovative assays, bioinformatics pipelines, and machine learning approaches to address complex challenges in prenatal and genomic medicine
IdentifAl	Dr. Liscovitch-Brauer earned her PhD from
Noa Liscovitch-Brauer, PhD	Bar-Ilan University, where she studied gene
"Leveraging machine-learning and Bayesian	expression in the mammalian brain using
approaches for prenatal detection of monogenic	advanced computational and imaging
disorders"	methods. She further honed her skills during
6/7 Saturday	postdoctoral fellowships at Tel Aviv
2:10-2:25 PM	University and the New York Genome Center,
	publishing impactful research on RNA
	editing, single-cell genomics, and CRISPR-based screens.

